Targeted systemic gene therapy with RGD4C/AAVP‐Grp78‐HSVtk plus GCV inhibits tumor growth of orthotopic GBM in immunocompetent mice, and efficacy is boosted by TMZ. This evidence concerns the gene HSPA5 and glioblastoma.